Sat, 23 Oct 2021

Beta-Thalassemia-Market-Insights

DelveInsight's Beta-Thalassemia market report thoroughly explains the Beta-Thalassemia historical and forecasted epidemiology, and Beta-Thalassemia market trends in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan).

Some of the Key Highlights from the Beta-Thalassemia Market Report

  • According to the National Organization for Rare Disorders, Beta-Thalassemia is a relatively rare autosomal recessive disorder in the United States, but it is one of the most common autosomal recessive disorders globally. The incidence of Beta-Thalassemia symptomatic cases in the general population is estimated to be 1 in every 100,000 people.
  • According to Kattamis et al. (2018) study titled "Changing patterns in the epidemiology of beta-thalassemia," approximately 1.5 percent of people worldwide are Beta-Thalassemia carriers.
  • Leading players such as Sangamo Therapeutics, Vifor Pharma, Imara, CRISPR Therapeutics, Vertex, and others are working diligently towards the development of novel treatments for Beta-Thalassemia.
  • Key pipeline therapies in the Beta-Thalassemia market include ST-400, VIT-2763, IMR-687, CTX001, and several others.
  • Vifor Pharma is developing VIT-2763, using its expertise in iron metabolism to treat diseases such as beta-thalassemia. Both the FDA and the EMA designated vamifeport as an orphan drug for the treatment of Beta-Thalassemia.
  • ST-400 is an ex-vivo gene-edited cell therapy that uses Sangamo Therapeutics' zinc finger nuclease (ZFN) genome editing technology to modify a patient's own hematopoietic stem cells (HSCs) into functional red blood cells using fetal hemoglobin.

Have queries? Request for sample @ Beta-Thalassemia Market Outlook

The Beta-Thalassemia market report covers current treatment practices, emerging drugs, Beta-Thalassemia market share of individual therapies, and current and forecasted Beta-Thalassemia market size from 208 to 2030, segmented by seven major markets.

Beta-Thalassemia: Overview

Beta Thalassemia is a genetic disorder that is inherited autosomally and recessively. It is an inherited blood disorder characterized by low functional hemoglobin levels. Beta Thalassemia is a type of blood disorder. Beta-Thalassemia is classified into three types: Beta-Thalassemia minor, Beta-Thalassemia intermedia, and Beta-Thalassemia major. Symptoms of Beta-Thalassemia can range from mild to severe, depending on the type.

Beta-Thalassemia Epidemiology Segmentation

The Beta-Thalassemia report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

  • Beta-Thalassemia Prevalent Population
  • Beta-Thalassemia Type-Specific Prevalent Population
  • Beta-Thalassemia Diagnosed and Treatable Prevalent Cases

Get the complete epidemiology analysis @ Beta-Thalassemia Epidemiology Insights

Beta-Thalassemia Treatment Landscape

Beta-Thalassemia has no specific treatment as it is a genetic disorder. The current treatment for Beta-Thalassemia focuses on delaying disease progression and relieving symptoms. Regular blood transfusions, medicines to remove excess iron from your body (called iron chelation therapy), surgery to remove the spleen, folic acid, surgery to remove the gallbladder, and bone marrow transplant are all possible treatments for Beta-Thalassemia.

The FDA-approved drugs used for Beta-Thalassemia treatment are Betibeglogene autotemcel (beti-cel), Reblozyl (luspatercept-aamt), Luspatercept (ACE-536), and others.

Beta-Thalassemia Market

The Beta-Thalassemia market is expected to witness the launch of upcoming therapies by key pharmaceutical companies including Sangamo Therapeutics, Vifor Pharma, Imara, and several others. The launch of emerging therapies such as ST-400, VIT-2763, IMR-687, and others are anticipated to provide a major push to the growth of the Beta-Thalassemia market size in the forecast period 2021-30 in the 7MM.

Beta-Thalassemia Pipeline Therapies and Key Companies

  • ST-400: Sangamo Therapeutics
  • VIT-2763: Vifor Pharma
  • IMR-687: Imara
  • CTX001: CRISPR Therapeutics /Vertex

For more information on the pipeline therapies and companies, visit Beta-Thalassemia Drugs in Development

Beta-Thalassemia Market Drivers

  • Increase in research activities
  • Advances in Genetics
  • Better Diagnostic Techniques

Beta-Thalassemia Market Barriers

  • Global Transfusion Burden
  • Continuity of Care
  • Lack of Sustainable Development

Scope of the Report

Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain, and France) and Japan)

Study Period: 2018-30

Beta-Thalassemia Key Companies: Sangamo Therapeutics, Vifor Pharma, Imara, CRISPR Therapeutics, Vertex, among others.

Beta-Thalassemia Key Pipeline Therapies: ST-400, VIT-2763, IMR-687, CTX001, and others.

Beta-Thalassemia Segmentation: By Geography, Beta-Thalassemia drugs

Analysis: Comparative and conjoint analysis of Beta-Thalassemia emerging therapies

Tools Used: SWOT Analysis

Case Studies

KOL's Views

Analyst's Views

Table of Contents

1.

Report Introduction

2.

Beta Thalassemia: Market Overview at a Glance

3.

Disease Background and Overview: Beta Thalassemia

4.

Beta Thalassemia Epidemiology and Patient Population (7MM)

5.

Beta Thalassemia: Country-wise Epidemiology

6.

Beta Thalassemia Treatments and Medical Practices

7.

Beta Thalassemia Current Treatment

8.

Beta Thalassemia Emerging Therapies

9.

7MM Beta Thalassemia Market Analysis

10.

Beta Thalassemia 7MM: Country-wise Market Analysis

11.

Beta Thalassemia United States Market Size

12.

Beta Thalassemia EU5 Market Size

13.

Beta Thalassemia Japan Market Size

14.

Beta Thalassemia Market Drivers

15.

Beta Thalassemia Market Barriers

16.

Report Methodology

17.

DelveInsight Capabilities

18.

Disclaimer

19.

About DelveInsight

Know more about report offerings @ Beta-Thalassemia Market

Related Reports

Thalassemia Market

DelveInsight's "Thalassemia - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Thalassemia, historical and forecasted epidemiology as well as the Thalassemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Hemophilia Market

DelveInsight's "Hemophilia - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Hemophilia, historical and forecasted epidemiology as well as the Hemophilia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Hemophilia A Market

Get comprehensive historical and forecast analysis of Hemophilia A Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Novo Nordisk, Shire, Sanofi, Bayer, Roche, Pfizer, among others.

Hemophilia B Market

Get comprehensive historical and forecast analysis of Hemophilia B Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Spark Therapeutics, UniQure Biopharma B.V., ApcinteX Ltd, Freeline Therapeutics, among others.

High Grade Glioma Market

Get comprehensive historical and forecast analysis of High Grade Glioma Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Merck, Orbus Therapeutics, Bayer, MedImmune, DNAtrix, among others.

Myocarditis Market

Get comprehensive historical and forecast analysis of Myocarditis Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Cardiol Therapeutics, among others.

Multiple Myeloma Market

Get comprehensive historical and forecast analysis of Multiple Myeloma Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Johnson & Johnson, Amgen, BioLineRx, Bristol-Myers Squibb, ExCellThera, Pfizer, Takeda, Precision BioSciences, Poseida Therapeutics, among others.

Fibromyalgia Market

DelveInsight's "Fibromyalgia - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Fibromyalgia, historical and forecasted epidemiology as well as the Fibromyalgia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Palmar Fibromatosis Market

DelveInsight's "Palmar Fibromatosis Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Palmar Fibromatosis, historical and forecasted epidemiology as well as the Palmar Fibromatosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Hemostasis Market

DelveInsight's "Hemostasis Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Hemostasis, historical and forecasted epidemiology as well as the Hemostasis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Sandeep Joshi

info@delveinsight.com

+1(919)321-6187

www.delveinsight.com

Connect With Us at:

LinkedIn | Facebook | Twitter

Tags: , , , , , , ,

See Campaign: https://www.delveinsight.com/Contact Information:Sandeep Joshi

info@delveinsight.com

+1(919)321-6187Tags:IPS, Reportedtimes, PR-Wirein, Menafn, iCN Internal Distribution, Extended Distribution, Research Newswire, English

More Boston News

Access More

Sign up for Boston News

a daily newsletter full of things to discuss over drinks.and the great thing is that it's on the house!